Tomas Yeo

Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4

Optimization and Characterization of the Antimalarial Activity of <i>N</i>-Aryl Acetamides that are Susceptible to Mutations in ROM8 and CSC1

Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activity

Systematic in vitro evolution in <i>Plasmodium falciparum</i> reveals key determinants of drug resistance

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo

Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b

Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission

Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets

Quinoxaline-Based Anti-Schistosomal Compounds Have Potent Anti-Malarial Activity

Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183

Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance

Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series

Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasome

Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite <i>Plasmodium falciparum</i> and Optimization Efforts

Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial Activity

A Variant PfCRT Isoform Can Contribute to <i>Plasmodium falciparum</i> Resistance to the First-Line Partner Drug Piperaquine